Top Page
Dimerix Limited
(Sydney:DXB)
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Dimerix Limited Business Overview & Revenue Model
Dimerix Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 737.87K | 583.48K | 8.98M | 6.46M | 4.44M | 2.34M |
| Gross Profit | 737.87K | 583.48K | 8.93M | 6.41M | 4.40M | 2.33M |
| EBITDA | -23.45M | -24.96M | -22.68M | -16.47M | -10.02M | -6.82M |
| Net Income | -23.31M | -17.08M | -13.80M | -10.49M | -6.37M | -4.49M |
Balance Sheet | ||||||
| Total Assets | 21.91M | 32.08M | 17.76M | 16.50M | 9.42M | 10.39M |
| Cash, Cash Equivalents and Short-Term Investments | 21.11M | 22.14M | 7.99M | 9.63M | 5.25M | 7.79M |
| Total Debt | 156.42K | 149.68K | 5.96M | 73.10K | 5.04M | 1.06M |
| Total Liabilities | 14.74M | 13.89M | 11.79M | 2.07M | 7.95M | 2.63M |
| Stockholders Equity | 7.17M | 18.19M | 5.96M | 14.42M | 1.47M | 7.76M |
Cash Flow | ||||||
| Free Cash Flow | -18.80M | -7.02M | -12.73M | -13.45M | -6.47M | -4.72M |
| Operating Cash Flow | -18.78M | -7.00M | -12.73M | -13.44M | -6.46M | -4.72M |
| Investing Cash Flow | -24.96K | -15.80K | -2.30K | -10.61K | 4.38K | 0.00 |
| Financing Cash Flow | 25.35M | 21.41M | 11.07M | 17.69M | 3.93M | 8.91M |
Dimerix Limited Technical Analysis
Dimerix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $8.27B | 161.85 | 14.52% | ― | 55.85% | 893.42% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 4.45% | 11.60% | -21.06% | |
56 Neutral | AU$37.04M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | AU$208.49M | ― | -37.20% | ― | ― | 32.02% | |
53 Neutral | AU$50.61M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
47 Neutral | AU$341.15M | ― | -524.68% | ― | 322.26% | -53.98% | |
44 Neutral | $350.49M | ― | -31.16% | ― | ― | 14.47% |
Dimerix Limited Corporate Events
Dimerix Limited has received a significant development milestone payment of ¥400 million (~AU$4.2 million) from FUSO Pharmaceutical Industries Ltd., marking a key step in their collaboration for the commercialization of DMX-200 in Japan. This milestone supports the recruitment for the ACTION3 clinical trial in Japan, potentially leading to further payments and royalties. The agreement with FUSO is part of Dimerix’s broader strategy to partner with multiple regional entities, potentially yielding up to ~AU$1.4 billion in upfront and milestone payments, as well as royalties, strengthening its market position and operational capabilities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). This move involves securities that have been issued as a result of options being exercised or other convertible securities being converted. The announcement signifies a strategic step in enhancing the company’s financial operations and market presence, potentially impacting stakeholders by increasing the liquidity and visibility of its securities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced the quotation of 4,039,351 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, effective June 24, 2025. This move reflects the company’s strategic efforts to enhance its market presence and potentially increase liquidity, which could have positive implications for its stakeholders and overall industry positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced a change in the director’s interest, specifically involving Sonia Poli. The change involved the exercise of 73,788 listed options, resulting in the acquisition of an equal number of ordinary shares. This transaction reflects a strategic adjustment in the director’s holdings, potentially signaling confidence in the company’s future performance.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the issuance of 2,842,233 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to capitalize on options being exercised or convertible securities being converted, potentially strengthening its financial position and market presence.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has released an investor presentation detailing their focus on developing therapies for kidney diseases with unmet clinical needs. The announcement highlights the company’s ongoing efforts in drug development and the potential impact on its operations and market positioning, while also acknowledging the inherent risks and uncertainties associated with such endeavors.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,630,800 fully paid ordinary securities on the ASX, effective June 17, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its position in the biotechnology sector and providing new opportunities for stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced the quotation of 457,377 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its capital structure, potentially improving its market position and providing additional resources for its ongoing pharmaceutical development projects.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,511,507 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, effective June 10, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and could potentially impact its financial standing and investor relations positively.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,342,120 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective June 5, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and potentially increase its market presence, which may have positive implications for its stakeholders and future growth prospects.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,692,019 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move, resulting from the exercise of options or conversion of other securities, is expected to enhance the company’s financial flexibility and potentially strengthen its market position by increasing its capital base.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the activation of its first clinical trial site in Japan for the ACTION3 Phase 3 clinical trial, which has triggered a milestone payment of ¥400 million from its Japanese partner, FUSO Pharmaceutical Industries Ltd. This development marks a significant step in Dimerix’s global clinical program for DMX-200, aimed at treating patients with FSGS, and underscores the company’s strategic partnerships and market expansion efforts in Japan. FUSO will handle clinical development costs and regulatory submissions in Japan, while Dimerix continues to focus on global trial delivery and licensing opportunities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the issuance of 1,250,448 ordinary fully paid securities, which will be quoted on the ASX under the code DXB. This move reflects the exercise of options or conversion of convertible securities, potentially impacting the company’s market presence and offering stakeholders increased investment opportunities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the upcoming expiry of its listed options (ASX:DXBO), which are exercisable at $0.154 until June 30, 2025. The company has sent notifications to option holders, and trading of these options will cease on June 24, 2025. This announcement is significant as it impacts stakeholders holding these options and reflects the company’s ongoing financial management strategies.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced the issuance of 1,189,968 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code DXB. This move, resulting from the exercise of options or conversion of other securities, is expected to enhance the company’s financial flexibility and potentially strengthen its market position.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 865,992 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced the successful completion of the sixth Independent Data Monitoring Committee (IDMC) review of its ACTION3 Phase 3 clinical trial for the DMX-200 drug, aimed at treating FSGS kidney disease. The IDMC found no safety concerns, allowing the trial to continue as planned, which supports the strong emerging safety profile of DMX-200. This development is significant for patients with FSGS, who currently have limited treatment options, and reinforces Dimerix’s position in the biopharmaceutical industry as it progresses towards potential marketing approval.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced a change in the substantial holding of its shares by Peter Meurs and Skiptan Pty Ltd, as trustee for the P & M Meurs Family Trust. The voting power of these entities has increased from 13.8% to 15.08% due to the exercise of options and on-market purchases. This change indicates a growing interest and investment by the substantial holder, which could impact the company’s shareholder dynamics and potentially influence its strategic decisions.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,503,918 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market positioning, reflecting a proactive approach to leveraging financial instruments for growth.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the Monsoon Twilight Investor Briefing in Melbourne, highlighting the status of their Phase 3 clinical trial for FSGS kidney disease and updates on commercial partnerships. This presentation underscores Dimerix’s commitment to advancing its late-stage clinical assets and strengthening its market position in the biopharmaceutical industry, potentially impacting stakeholders by providing insights into the company’s progress and future opportunities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the issuance of 12,350,583 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially impacting its market position and offering opportunities for stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 1,808,257 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategic efforts to enhance its market presence and potentially increase its shareholder base, reflecting its ongoing commitment to growth and expansion in the biotechnology sector.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the quotation of 948,636 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB. This move follows the exercise of options or conversion of other convertible securities, potentially enhancing the company’s liquidity and market presence.
Dimerix Limited has announced the quotation of 3,474,780 fully paid ordinary securities on the ASX, following the exercise of options or conversion of convertible securities. This move is part of the company’s ongoing efforts to enhance its market presence and provide liquidity to its stakeholders, potentially impacting its operational capabilities and industry positioning.
Dimerix Limited has received an initial payment of US$30 million from Amicus Therapeutics as part of a licensing agreement for the commercialization of DMX-200 in the United States. This agreement, along with others, positions Dimerix to potentially earn up to AU$1.4 billion in upfront and milestone payments, plus royalties, significantly enhancing its financial and operational capabilities to advance DMX-200 as a treatment for FSGS. The company retains rights to DMX-200 in territories not covered by existing agreements and continues to seek additional licensing opportunities.
Dimerix Limited has announced the quotation of 581,561 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective May 1, 2025. This move reflects the company’s ongoing efforts to enhance its market presence and provide additional liquidity for its stakeholders.
Dimerix Limited announced a US licensing transaction for their Phase 3 clinical asset, DMX-200, aimed at treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The company is hosting an investor webinar to discuss this development and the progress of their clinical trials. This move is significant for Dimerix as it could enhance their market positioning by addressing an unmet medical need and potentially securing market exclusivity through Orphan Drug Designation incentives in the US and Europe.
Dimerix Limited and Amicus Therapeutics have entered into an exclusive license agreement for the commercialization of Dimerix’s Phase 3 drug candidate DMX-200 in the United States. This agreement grants Amicus the rights to commercialize DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no FDA-approved therapies, while Dimerix retains commercialization rights outside the U.S. The deal includes an upfront payment of US$30 million to Dimerix, with potential milestone payments and royalties based on sales and development achievements. This collaboration is expected to enhance Dimerix’s market positioning by leveraging Amicus’s regulatory and commercial expertise, potentially transforming treatment options for FSGS patients.
Dimerix Limited announced significant progress in its quarterly activities report, highlighting a positive meeting with the FDA that confirmed proteinuria as an acceptable endpoint for marketing approval of DMX-200 in the US. The company also secured a development and license agreement with Fuso Pharmaceutical Industries for DMX-200 in Japan, potentially worth up to ¥10.5 billion, and continued to receive strong partnering interest globally. These developments, alongside its inclusion in the S&P ASX All Ordinaries, position Dimerix favorably in the biopharmaceutical industry, with potential implications for stakeholders through expanded market reach and financial growth.
Dimerix Limited has announced the issuance of 20,250 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB as of April 28, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor relations positively.
Dimerix Limited announced a significant development in its Phase 3 clinical trial for DMX-200, as the FDA confirmed proteinuria as an acceptable primary endpoint for full marketing approval in the US for treating Focal Segmental Glomerular Sclerosis (FSGS). This decision aligns with Dimerix’s previous clinical findings and could potentially expedite the drug’s market entry, offering hope for patients with this progressive disease.
Dimerix Limited has announced the issuance of 13,125 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code DXB. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
Dimerix Limited announced the quotation of 152,501 new ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB. This move reflects the company’s ongoing efforts to enhance its capital structure and potentially improve its market positioning, offering stakeholders an opportunity to engage with the company’s growth trajectory.
Dimerix Limited announced its participation in the ASX CEO Connect event, highlighting its Phase 3 clinical asset in kidney disease. The company is working on DMX-200, which has shown promising results in addressing the unmet medical needs of FSGS, a rare and severe kidney disease. With Orphan Drug Designation in the US and Europe, Dimerix is poised for potential market exclusivity and accelerated regulatory pathways, which could significantly impact its market position and offer new hope for patients with limited treatment options.
Dimerix Limited has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective April 10, 2025. This move reflects the company’s ongoing efforts to enhance its financial flexibility and strengthen its market presence, potentially benefiting stakeholders by increasing liquidity and visibility in the market.
Dimerix Limited has updated its Securities Trading Policy to align with current listing rules, reflecting its ongoing commitment to regulatory compliance. This update comes as the company continues to advance its Phase 3 clinical asset in kidney disease, potentially impacting its market operations and stakeholder interests.
Dimerix Limited has announced the quotation of 5,352 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of April 4, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market positioning, which could have implications for its stakeholders by increasing liquidity and potentially attracting more investors.
Dimerix Limited announced the quotation of 12,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code DXB, effective April 2, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing research and development initiatives, potentially impacting its market positioning and stakeholder interests positively.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the HealthInvest Summit 2025 in Sydney, highlighting the status of its ACTION3 Phase 3 clinical trial for FSGS kidney disease. The presentation will also cover updates from a recent FDA meeting and discuss the commercial potential of their therapies. This announcement underscores Dimerix’s strategic focus on addressing unmet medical needs in the kidney disease market, potentially strengthening its position in the biopharmaceutical industry and offering significant implications for stakeholders, given the lack of approved treatments for FSGS.